Abeona Therapeutics Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference

Always a pleasure. Thank you, Kristin.

Absolutely. Abeona, as you know, is a commercial stage cell and gene therapy company. We are pioneering medicines for the highest unmet needs, and our flagship product is ZEVASKYN, which launched late last year, in a disease called recessive dystrophic epidermolysis bullosa. Patients with a lot of chronic wounds that lead to complications, and they do not have normal lives. And ours is the only autologous cell therapy that addresses the gene deficiency. And the launch is well underway. Other than ZEVASKYN, we also have our partnered programs with Ultragenyx, and Taysha, and Beacon. And we have an early-stage preclinical asset in the PSMA prostate cancer space that is going into clinic next year. So many, many exciting catalysts on the way.

Yeah. We have 7 qualified centers. Most recently, we activated Cincinnati Children's, which is one of the largest EB centers in the U.S., also very well recognized globally. We have a wide footprint geographically from the west to the east. Can you hear me okay?

Yeah. Starting from California and the West Coast, we have the Colorado, Chicago area, Texas, the East Coast.

These are all very well-known centers. It is important that we activate onboard centers that are well respected and trusted by these patients because this is a patient community that requires lots of handling and comorbidities, complications, GI dilatation, pain management, infection management. Onboarding these well-known centers is going to help us with, now that they are active with patient identification and moving them through the process. There are additional centers that are interested in bringing ZEVASKYN onto those centers also.

Yeah. We don't match a patient to a center. That's typically done either based on patient's own preference, where they're comfortable going with, or the relationship that the referring doctor has got with one center versus the other. Sometimes we have seen insurance companies actually dictate, because it depends on the payer plan of that patient, if the center is in-network or out-of-network, that also helps guide as to what's the right center to go. Like I said, I think we do have centers that clearly want to bring ZEVASKYN on board, and that's only going to further expand our geographic footprint and minimize the travel burden for these patients.

The area that's most exciting to these patients is the fact that they have a treatment option that can provide long-term durable benefit by healing their wounds, reducing pain. The fact that they don't have to spend many hours in bandage dressing changes, they can live their life. This is huge for these people. There is a very high unmet need, even though we have multiple therapeutic options. Of course, we know that this is a surgical application, and patients are hesitant. Hesitant in the sense they want to know what the process entails. That also depends on the age. You've got young adults and adults who have spent their life going through many complicated procedures, so they kind of know what to expect. But then you have other younger or parents who want to know what involves.

We've actually helped bridge that or mitigate that by putting these patients or prospective patients in touch with people who have gone through our clinical trials. We have a group of patients called Strong Together Network. These are patients who have received ZEVASKYN not just once, but twice because they have seen the benefit. By helping bridge make those connections, that's really helping prospective patients understand what to expect.